An international, expert panel of seven retina specialists discuss PDR in 2021 from diagnosis through to treatment and complications.
Adnan Tufail and Paolo Lanzetta discuss the best approaches to neovascular AMD regimens during and post the COVID-19 pandemic.
EURETINA are launching a Women’s Leadership Programme to fulfill the Society’s mission to nurture diversity in leadership at all levels in the field of retina.
Preview the Lamellar Macular Defects course by professor Ricarda Schumann, Professor of ophthalmology, Ludwig Maximilians University Munich, Germany.
Preview the OCTs in age-related macular degeneration course by Doctor Aude Ambresin, a specialist physician in ophthalmology and FMH ophthalmosurgery, in Switzerland.
Preview the vitreomacular traction course by professor Siegfried Priglinger, medical director of the university eye clinic, Ludwig Maximilians University Munich, Germany.
Novartis International AG (SIX: NOVN; NYSE: NVS) has announced the acquisition of Vedere Bio, a
Real-world data on fluocinolone acetonide implant treatment with recurrent diabetic macular oedema (DMO) supports fewerclinical visits over 3 years.
Clinical researchers at the NHS Foundation Trust, Sheffield, UK have found that real-world evidence on
Regenxbio Inc. has announced the first patient dosing of Phase II for RGX-314 gene therapy treatment for wet AMD
REGENXBIO Inc. (Nasdaq: RGNX), a clinical-stage biotechnology company has announced that the first patient has
Clinical research on genotype-phenotype correlations in retinitis pigmentosa (RP) are in preparation for gene therapy studies.
Researchers based at the University of Tübingen, Germany have published a clinical study on retinitis
COVID-19 findings show increased microvascular vessel changes in the retina between infected and non-infected patients
Researchers in the Luigi Sacco Hospital, Milan, have reported that important changes in the retina
Novartis reported two new post-hoc analyses of the Phase III HAWK and HARRIER clinical trials at the EURETINA 2020 virtual congress
Novartis have reported two new post-hoc analyses of the Phase III HAWK and HARRIER clinical